Document Detail


Autophagy induction by the 30-100kDa fraction of areca nut in both normal and malignant cells through reactive oxygen species.
MedLine Citation:
PMID:  20920876     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Areca nut (AN) is an addictive carcinogen used by about 200-600 million people worldwide. Some AN components are shown to induce apoptosis; however, we previously demonstrated that AN extract (ANE) and the 30-100kDa fraction of ANE (ANE 30-100K) induced autophagy-like responses, such as swollen cell morphology, empty cytoplasm, acidic vesicles, and LC3-II accumulation, in an oral cancer cell line, OECM-1. To further assess the responses of other cell types to ANE 30-100K, we used both normal and malignant cells as the targets of ANE 30-100K and found that normal oral fibroblasts (CMT415), peripheral blood lymphocytes (PBLs), Jurkat leukemia T cells, and esophageal carcinoma cells (CE81T/VGH) exhibited similar responses after ANE 30-100K challenge. ANE 30-100K drastically increased acidic vesicle-containing PBLs isolated from two independent donors (from 0.1% to 92.1% and 2.9% to 64.2%). Furthermore, both ANE- and ANE 30-100K-induced LC3-II accumulation in CMT415 and CE81T/VGH was further increased in the presence of the lysosomal protease inhibitors (pepstatin A, E64d, and leupeptin). On the other hand, ANE 30-100K also increased the level of intracellular reactive oxygen species (ROS), and the ROS scavengers, N-acetylcysteine (NAC) and Tiron, inhibited ANE 30-100K-induced cell death and LC3-II accumulation. Collectively, these results suggest the existence of an autophagy-inducing AN ingredient (AIAI) in ANE 30-100K, which renders ANE as an autophagic flux inducer through ROS in both normal and malignant cells.
Authors:
Mei-Huei Lin; Wan-Fang Hsieh; Wei-Fan Chiang; Wen-Zhai Hong; Yu-Rung Hsu; Yon-Chi Cheng; Tai-Chi Chen; Kai-Cheng Hsu; Pin-Yan Lin; Pin-Yan Lina; Shyun-Yeu Liu; Young-Chau Liu
Related Documents :
16404156 - Transduced human copper chaperone for cu,zn-sod (pep-1-ccs) protects against neuronal c...
11678606 - On the mechanism of cr (vi)-induced carcinogenesis: dose dependence of uptake and cellu...
11597896 - Et-1 stimulates pulmonary arterial smooth muscle cell proliferation via induction of re...
11284726 - Hierarchies of atp-consuming processes: direct compared with indirect measurements, and...
3940186 - Oncogenic transformation of c3h10t1/2 mouse embryo cells by x-rays, hyperthermia, and c...
10954586 - Puralpha: a multifunctional single-stranded dna- and rna-binding protein.
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Oral oncology     Volume:  46     ISSN:  1368-8375     ISO Abbreviation:  Oral Oncol.     Publication Date:  2010 Nov 
Date Detail:
Created Date:  2010-10-29     Completed Date:  2011-04-20     Revised Date:  2011-05-17    
Medline Journal Info:
Nlm Unique ID:  9709118     Medline TA:  Oral Oncol     Country:  England    
Other Details:
Languages:  eng     Pagination:  822-8     Citation Subset:  IM    
Copyright Information:
Copyright © 2010 Elsevier Ltd. All rights reserved.
Affiliation:
Department of Biotechnology, Chia Nan University of Pharmacy, Tainan, Taiwan, ROC.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Areca / chemistry*
Autophagy / drug effects*
Blotting, Western
Cell Line, Tumor
Female
Fibroblasts / drug effects,  metabolism
Humans
Male
Mouth Neoplasms / chemically induced*
Oxidative Stress / drug effects
Plant Extracts / pharmacology*
Reactive Oxygen Species / metabolism*
T-Lymphocytes / drug effects,  metabolism
Up-Regulation / drug effects
Chemical
Reg. No./Substance:
0/Plant Extracts; 0/Reactive Oxygen Species
Comments/Corrections
Erratum In:
Oral Oncol. 2011 Mar;47(3):228
Note: Lina, Pin-Yan [corrected to Lin, Pin-Yan]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Automatic microvolt T-wave alternans identification in relation to ECG interferences surviving prepr...
Next Document:  Phase II study of vinorelbine/cetuximab in patients with recurrent/metastatic squamous cell carcinom...